

## for Canine Bacterial Eye Infections **Gentocin**<sup>®</sup> **Durafilm**<sup>®</sup>

(GENTAMICIN SULFATE AND BETAMETHASONE) Ophthalmic Solution

A drop that ACTS like an ointment



Consistent, dependable quality



# **Gentocin<sup>®</sup> Durafilm<sup>®</sup> Ophthalmic Solution**

# Three powerful reasons to treat canine bacterial eye infections with Gentocin Durafilm

- GENTAMICIN SULFATE—A broad-spectrum antibiotic with highly effective results against gram-positive bacterial and gram-negative bacterial infections of the eye
- BETAMETHASONE ACETATE—A rapid-acting anti-inflammatory corticosteroid that provides symptomatic relief from bacterial, allergic, or traumatic tissue responses
- DURAFILM—An aqueous colloidal solution that coats the conjunctiva to maintain extended contact with the active, therapeutic ingredients

# A proven performer that goes on like a drop... coats like an ointment

- Prolonged contact, efficacy, and safety
- Unique formulation with a history of success
- Supports treatment and compliance



Gentocin<sup>®</sup> Durafilm<sup>®</sup> (GENTAMICIN SULFATE AND BETAMETHASONE) Ophthalmic Solution



Corticosteroids are contraindicated in initial treatment of corneal ulcers. The antibiotic sensitivity of the infective organism in bacterial conjunctivitis should be determined prior to the use of this preparation. Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy. A transient stinging sensation, usually expressed as some form of resentment by the animal, following topical application of the drug, has been noted in a small number of cases. Usually this does not require discontinuance of therapy. See Package Insert for full safety information.

## **Optimmune**<sup>®</sup> **Ophthalmic Ointment**

# In cases of KCS\* and Pannus, Optimmune treats the underlying immune-mediated cause<sup>1</sup>

- Increases natural tear production by restoring lacrimal gland production<sup>†</sup>
- Promotes and protects conjunctival and corneal health while reducing inflammation
- Offers prolonged contact time, allowing a safer and lower dose concentration
- Sterile and preservative-free formulation—reduces risk of irritation or secondary infection
- Stable shelf life of up to 24 months; refrigeration not required
- Schirmer Tear Test can rule out KCS or establish a baseline in predisposed breeds

Left untreated, canine KCS and Pannus can lead to blindness<sup>2</sup>—choose Optimmune for consistent quality, safety, efficacy, and dose concentration

### **Incidence of KCS**

Chronic and/or undiagnosed KCS has been shown to affect over 8% of dogs in predisposed breeds, and over 4.5% of the general canine population.<sup>3</sup>



Optimmune. (0.2% Cyclosporine, USP) Ophthalmic Ointment

For ophthalmic use in dogs only. The safety of OPTIMMUNE® Ophthalmic Ointment has not been determined in cases of preexisting viral or fungal ocular infections, nor in puppies, pregnant bitches, or dogs used for breeding. In clinical trials, ocular and periocular inflammatory reactions, transient hyperemia, epiphora, mild discomfort of the eye, and mild alopecia were reported in a small number of treated dogs. For full prescribing information, including directions for use, precautions and adverse reactions, see accompanying package insert.

\*KCS=keratoconjunctivitis sicca

<sup>+</sup>Clinical improvement in cases of KCS is not necessarily dependent on an increase in aqueous tear production.

References: 1. Williams DL. Immunopathogenesis of keratoconjunctivitis sicca in the dog. Vet Clin North Am Small Anim Pract. 2008;38:251-268. 2. Sanchez RF, Innocent G, Mould J, Billson FM. Canine keratoconjunctivitis sicca: disease trends in a review of 229 cases. J Small Anim Pract. 2007;48:211-217. 3. Peirce V, Williams D. Evaluation of breed variation of Schirmer tear test values in 1000 ophthalmoscopically normal dogs. BSAVA Congress 2006. Abstract. PRODUCT INFORMATION

## Optimmune<sup>•</sup> (0.2% Cyclosporine, USP)

#### For ophthalmic use in dogs only.

#### Sterile

CAUTION: US Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Each gram of OPTIMMUNE® Ophthalmic Ointment contains 2 mg of cyclosporine, USP; petrolatum, USP; corn oil, NF; petrolatum and lanoin alcohol. Cyclosporine (cyclosporin A), the active ingredient of OPTIMMUNE® Ophthalmic Ointment, is a cyclic undecapeptide metabolite of the fungus Tolypocladium inflatum gams. MODE OF ACTION: When applied ophthalmically, cyclosporine is believed to act as a local immunomodulator of diseases suspected to be immunemediated such as keratoconjunctivitis sicca (KCS) and chronic superficial keratitis (CSK). In the management of KCS, the mechanism by which cyclosporine causes an increase in lacrimation is poorly understood. Clinical improvement in cases of KCS is not necessarily dependent on an increase in aqueous tear production (as measured by the Schirmer Tear Test (STT). See EFFICACY.

INDICATIONS: OPTIMMUNE® Ophthalmic Ointment is indicated for management of chronic keratoconjunctivitis sicca (KCS) and chronic superficial keratitis (CSK) in dogs.

PRECAUTIONS: The clinical effects of OPTIMMUNE® Ophthalmic Ointment have not been determined in dogs with KCS due to the following conditions: congenital alactima, sulfonamide usage, canine distemper virus, metabolic disease, surgical removal of the third eyelid gland, and facial nerve paralysis with loss of the palpebral reflex. Some of the underlying conditions which may lead to KCS can be either transient (eg, facial nerve trauma) or correctable with appropriate treatment. Consequently, recovery from clinical signs attributed to KCS may be observed and treatment options may need reconsideration.

When switching to cyclosporine from another therapeutic agent (eg, frequent application of an artificial tear preparation) for KCS or CSK, it should be kept in mind that clinical efficacy is not necessarily apparent immediately after initiation of OPTIMMUNE® Ophthalmic Ointment therapy. Several days to a few weeks may be required before the clinical effects of OPTIMMUNE® Ophthalmic Ointment are of sufficient magnitude such that previously initiated therapy can be safely withdrawn. Abrupt cessation of a therapeutic agent immediately upon initiation of OPTIMMUNE® Ophthalmic Ointment therapy can result in rapid clinical relapse which may be erroneously interpreted as an adverse reaction to OPTIMMUNE® Ophthalmic Ointment.

The safety of OPTIMMUNE® Ophthalmic Ointment has not been determined in cases of preexisting viral or fungal ocular infections. It is recommended that in such cases, OPTIMMUNE® Ophthalmic Ointment therapy be delayed until the fungal/viral ocular infection has been successfully treated.

The safety of OPTIMMUNE® Ophthalmic Ointment in puppies, pregnant bitches, or dogs used for breeding has not been determined. EFFICACY: 1. KCS A well-controlled clinical field trial was conducted by veterinary ophthalmologists in 9 states and included 132 dogs afflicted with KCS of which 124 were evaluated for efficacy. Dogs were randomly assigned to BID treatment with either 0.2% (OPTIMMUNE® Ophthalmic Ointment) or 0% (placebo vehicle) cyclosporine ophthalmic ointment for 12 weeks. Treatment with OPTIMMUNE® Ophthalmic Ointment resulted in an average 8 to 9 mm increase in STT by the end of the study period (vs 3 to 4 mm for the placebo vehicle). Most of the increase in STT, approximately 6 mm, occurred in the first week of therapy. Some dogs improved clinically (ie, exhibited a decrease in conjunctival and/or corneal pathology) without an increase in STT values. This is thought to occur through suppression of inflammation by cyclosporine on the ocular surface. In this clinical field trial, OPTIMMUNE® Ophthalmic Ointment therapy was also associated with an improvement in clinical signs in comparison to the placebo. Blepharitis, blepharospasm, and "other signs of ocular discomfort" (eg, pawing at eyes), were markedly reduced. Improvement in conjunctival health as manifested by reduced conjunctival hypertrophy, reduced hyperemia, reduced conjunctival discharge volume, and improved character of discharge was evident. Improvement in corneal health as manifested by improved corneal surface contour, reduced corneal edema and corneal neovascularization was also noted. Overall improvement was noted in 81% of eyes treated with OPTIMMUNE® Ophthalmic Ointment.

Withdrawal of OPTIMMUNE® Ophthalmic Ointment therapy resulted in rapid clinical regression in all but one test eye indicating the need for long-term continual therapy for almost all cases of chronic KCS.

2. CSK The efficacy of OPTIMMUNE® Ophthalmic Ointment was determined in a historical controlled clinical field trial conducted by veterinary ophthalmologists in four countries and included 36 dogs afflicted with CSK. Dogs, primarily German shepherds, a breed disposed to CSK (German shepherd pannus), were treated twice daily with OPTIMMUNE® Ophthalmic Ointment for 6 weeks. Clinical improvement was noted by the investigators in 90.3% of eyes treated with OPTIMMUNE® Ophthalmic Ointment when compared to baseline. SAFETY: A target animal safety study and clinical field studies with OPTIMMUNE® Ophthalmic Ointment showed a wide safety margin in adult dogs. In the 6-month target animal safety study, dogs were subjected twice daily to up to 10 times the approved concentration of OPTIMMUNE® Ophthalmic Ointment. No apparent toxicity or adverse reactions were observed. Dogs in this study were vaccinated with commercially available vaccines. No effect on antibody titer response was noted. Epiphora was noted in all groups, including the placebo group, and was not associated with any inflammatory change, nor was there any correlation to gross and histopathological changes. ADVERSE REACTIONS: In the KCS clinical field trial, there were 20 adverse reactions reported out of 132 cases enrolled. This corresponds to an adverse reaction rate of 12.9% (13 of 101 cases) for OPTIMMUNE® Ophthalmic Ointment treated dogs and 22.6% (7 of 31) for placebo treated dogs. The reactions described were primarily ocular and periocular inflammatory reactions. These were likely a function of therapy being unable to fully control the keratoconjunctivitis, rather than a true "adverse reaction." Similarly, in the CSK trial, of 36 cases evaluated for safety, adverse reactions were noted in 2 animals (5.6%). One involved transient hyperemia, epiphora, and mild discomfort of the eye. The other involved periocular/palpebral inflammation and mild alopecia.

On rare occasion, instillation of OPTIMMUNE® Ophthalmic Ointment may be associated with local irritation as manifested by periocular redness, lid spasm, and excessive rubbing. As the eyes of dogs with KCS often demonstrate considerable inflammation, it will be difficult to determine whether this local irritation constitutes a hypersensitivity to OPTIMMUNE® Ophthalmic Ointment. If this ocular irritation persists beyond 7 days, hypersensitivity to a component of OPTIMMUNE® Ophthalmic Ointment should be suspected and therapeutic options reassessed.

DOSAGE AND ADMINISTRATION: Remove debris with suitable nonirritating solutions. Apply a 1/4 inch strip I ↔ I of ointment to the affected eye(s) every 12 hours. The ointment may be placed directly on the cornea or into the conjunctival sac.

It is recommended that dogs exhibiting chronic recurring conjunctivitis be tested for adequate tear production to determine if they are suffering from early stages of chronic KCS.

For best results in treating KCS, cyclosporine ophthalmic ointment should be administered early in the course of the disease before irreversible damage to the lacrimal tissue, or dense corneal scarring or pigmentation occurs.

Dogs afflicted with KCS or CSK will most likely require lifelong <u>consistent</u> therapy (see **EFICACY** section above). For CSK, because environmental factors such as ultraviolet (UV) radiation are implicated in the pathogenesis, clinical signs may subside in the winter months when light intensity is reduced or if the dog is moved to a lower altitude, or indoors, and thus exposed to less UV radiation.<sup>1</sup>

In cases refractory to cyclosporine, the diagnosis should be reevaluated and a different course of therapy considered. Periodic reassessment of the need for OPTIMMUNE® Ophthalmic Ointment therapy is recommended.

HOW SUPPLIED: OPTIMMUNE® Ophthalmic Ointment is available in a 3.5 g tube, carton of 6 (NDC 0061-1088-01).

STORÄGE CONDITIONS: Store between 2° and 25° C (36° and 77° F). KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. REFERENCE: Roberts, Steven M. Pannus. In: Kirk's Current Veterinary Therapy XII, Small Animal Practice. Philadelphia: W.B. Saunders Co; 1995;1245-1248.

Copyright © 2012 Intervet Inc. a subsidiary of Merck & Co. Inc., Summit, NJ 07901. All rights reserved.

Rev. 9/12

#### PRODUCT INFORMATION NADA #34-267, Approved by FDA.

### Gentocin® Durafilm®

(GENTAMICIN SULFATE AND BETAMETHASONE) Sterile Ophthalmic Solution Antimicrobial and Anti-inflammatory

#### For Use in Dogs Only

CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION GENTOCIN DURAFILM Ophthalmic Solution is a sterile preparation for topical application. Each mL of buffered solution (pH approximately 6.5) contains gentamicin sulfate equivalent to 3 mg gentamicin base, 1 mg betamethessone acetate equivalent to 0.89 mg betamethassene alcohol, polyoxyl 40 stearate, polyentavy 35 castor al, elektre disolutim, 0.11 mg betamethassene alcohol, polyoxyl 40 stearate, polyentavy 35 castor al, elektre disolutim, 0.11 mg betamethassene guidente for and water for injection g.s. Gentramicin is a bacteriaidal antibiotic of the aminoglycoside group derived from Microanonospora purpure of the Actionnyces group. It is a powder, while to buff in color, basic in nature, readily solubil in water and highly stable in solution.

137435 R5

Betamethasone, a synthetic derivative of prednisolone, is 9-alpha-fluoro-16-beta-methyl-prednisolone.

INDICATIONS GENTOCIN DURAFILM Ophthalmic Solution is indicated for the treatment of external eye infections and inflammation in dogs.

Clinical reports indicate it is useful for the management of some cases of pigmentary keratitis and pannus. Temporary remission of some of the pathological lesions of the aforementioned conditions have been noted following therapy with GENTOCIN DURAFILM Ophthalmic Solution.

DOSAGE AND ADMINISTRATION The topical applications of CEVTOCIN DURAFILM Ophthalmic Solution should, in each instance, be administered to meet the specific needs of the individual case. One or two days of the solving more be instilled in the conjunctived sort three of nor times a dow. Thereafter, the frequency of the docage may be reduced but care should be taken not to discontinue therapy premoturely. In chronic conditions, withdrawel of heatment should be carried out by gradoully decessing the frequency of opplication.

CONTRAINDICATIONS Corticosteroids are contraindicated in initial treatment of corneal ulcers. GENTOCIN DURAFIUM Ophthalmic Solution is contraindicated in ocular conditions where there is deep ulceration without vascularization and in conditions of viral origin before healing has commenced.

WARNINGS Not for human use. Keep this and all drugs out of the reach of children. Clinical and experimental data have demonstrated that carticosteroids administered analy or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate periodure parturition followed by dystoxia, field ladent, fortile adjocation, and mentifis.

Additionally, contracsteroids administered to dogs, rabbits, and radents during pregnancy have produced cleft palate. Other congenital anomalies including deformed forelegs, phocomelia, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy.

PRECAUTIONS The antibiotic sensitivity of the infective organism in bacterial conjunctivitis should be determined prior to the use of this preparation. The preparation is contraindicated in the case of nonsusceptible microarganisms. In deep-seated infections or when systemic infection threatens, specific systemic antibiotic or sufformative flavor should be employed.

Extended use of topical contracteroids may cause increased intraocular pressure in susceptible patients, In prolonged therapy, it is advisable to messure intracacular pressure. In human medicrie, in diseases that cause thinming of the connexe, performation has been known to home occurred with the use of topical stensiol. Use of contracteroids, depending on dose, duration, and specific steroid, may result in inhibition of endogenous stenoid production following drug withdrawed. In patients presently receiving or recently withdrawn from systemic contracteroid treatments, therapy with a rapidly acting contracteroid should be considered in segurity lestsoid situations.

ADVERSE REACTIONS SAP and SGPT (ALT) enzyme elevations, polydipsia, and polyuria have occurred following parenteral or systemic use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs.

Cushing's syndrame in dogs has been reported in association with prolonged or repeated steroid therapy. A transient stinging sensation, usually expressed as some form of resemiment by the animal, following topical application of the daug, has been noted in a small number of cases. Usually this does not require discontinuous of therapy.

To report an adverse reaction, product-related problem, or human exposure, please call Merck Animal Health Technical Services at 1-800-224-5318.

To obtain a copy of the Material Safety Data Sheet (MSDS), call 1-800-770-8878.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888+FDA-VETS or <u>http://www.fda.gov/AnimalVeterinary/SafetyHealth/default.htm</u> CLINICAL PHARMACOLOGY GENTOCIN DURAFILM Ophthalmic Solution incorporates polyaxyl 40 stearate and polyethoxy 35 castor ali which provide a calloidal dispersion of active ingredients. This aqueous calloidal solution offers specific advantages in treating eye conditions. DURAFILM covers the conjunctive with a thin, clear, quickly spreading film which carries therapeutic components to accessible structures and maintains prolonged contract.

GENTOCIN DURAFILM Ophthalmic Solution provides the antibacterial properties of gentamicin sulfate plus the anti-inflammatory action of betamethasone acetate.

Gentamicin sulfate, a wide-spectrum antibiotic, is a highly effective topical treatment in primary and secondary bacterial infections of the eye and surrounding tissues. Gentamicin is bacteriadal in vitro against a wide variety of gram-positive and gram-negative bacteria. Concentrations of gentamicin sulfate required to inhibit growth of gram positive and gram-negative bacteria. Concentrations of bacteria tested were less than those of neomycin in most instances.<sup>1</sup> Gentamicin is active against most gram-negative bacteria including *Pseudomance aeruginase*, indele positive and negative *Protess* species, *Eschericita coli*, *Kelsiella pneumoniae, Aerobacter aeruginapens, and Neisseria.* Gentamicin is ado active against stratins of gram-positive bacteria including. *Staphylocccus* species and *Graup*. A *Bert-Hamolytic*. Stapet and the species and the species of the species of the species of the species of the species and the species of the species of the species of the species of the species and the species of the species of the species of the species of the species providence including. *Staphylocccus* species and *Graup*. Als *Bert-Hamolytic*. Stapet *Conce*.

Betamethasene produces harmonal and metabolic effects cammon to all advancantical steroids, and in low dasage affacts anti-inflammatory, anti-allergic, and anti-fueumatic effects. Studies in man show the gluccanticial activity of betamethasena to be 10 to 15 times greater than predisione. Betamethasene helps control excessive tissue reaction to infections, allergens, and thruma. The controlic control the inflammatory and exudate phases of eye conditions, particularly tasse affecting the anterior chamber and acternal structure of the eye. However, they do not cutal the growth of the causative againsts. Betamethasene therapy may reduce the domaging sequeles in certain eye diseases and injuries as well as as a structure of the eye. However, they do not cutal the growth of the causative againsts. Betamethasene therapy may reduce the domaging sequeles in certain eye diseases and injuries as well as as finalmantian, and papers to talter the usual tissue response to injury. In initial cause the phases of inflammation, local application of betamethasene provides prompt, symptomatic relief, accomplishing temporary control of the exualitive phases, whether of bacterial, allergic, or traumatic origin. Betamethasene tasks in which inflammator and the star resource in temporary control of the exualitive phases, whether of bacterial, allergic, or traumatic origin.

ANIMAL SAFETY In a traget animal safety study, GENIOCIN DURAFLUM Ophthalmic Solution was administered for 14 consecutive doys to healthy Beagle dags at a dass of 2 drops/yere 4 times daily (1X maximum daily dose; 8 dogs), 4 dops/ 4 drops/ evel times daily (2X maximum daily dose; 8 dogs), and 6 drops/yere (3X maximum daily dose; 8 dogs). Eight dogs received d drops of stelle saline/ grey 4 times daily (Control XX). A mail serous ocular discharge was observed in GENTOCIN DURAFLIM hereded dogs in doserelated manner, which resolved within a few hours of dosing. Mild bialtered schear lenders was seen in the 3X group on Day 2, and was evident in a dose proportional manner in all three tratment groups dree 1 days of dasing. 1X group (3 d B dogs), 2X group (7 d B dogs) and 3X group (8 d B dogs). In dogs from each GENTOCIN DURAFLIM netted group, Aranges in hematological parameters included neurosphane ALT, SAP, GGT, trafycerides, albumin, globulin and total protein leves and decreessed (K levels. Unite specific growity was decreased in each GENTOCIN DURAFLIM treated groups of the treated arous otos had increased foot communities and base and the GENTOCIN DURAFLIM treated groups of treated arous otos had increased foot communities and base and the GENTOCIN DURAFLIM. Treated arous dos had increased foot communities and base and the control arous.

HOW SUPPLIED GENTOCIN DURAFILM Ophthalmic Solution, is supplied in 10 mL squeeze dropper bottles with a 5 mL fill, in banded units of 10, NDC 0061-0100-01.

#### Store between 2° and 25°C (36° and 77°F).

Protect from light.

#### REFERENCE

<sup>1.</sup> Weinstein MJ, Luedemann GM, oden eM, Wagman GH. Gentamicin, a new broad-spectrum antibiotic complex. Antimicrob Agents and Chemother. 1963:1 — 7.

Made in Germany Rev. 09/13 Copyright © 1995, 2011, 2013 Intervet Inc., a subsidiary of Merck & Co. Inc., Whitehouse Station, NJ, USA. All rights reserved

Distributed by: Intervet Inc d/b/a Merck Animal Health



### **PROTECTION FOR** THE CANINE EYE

## for Canine Bacterial Eye Infections Gentocin<sup>®</sup> Durafilm<sup>®</sup>

(GENTAMICIN SULFATE AND BETAMETHASONE) **Ophthalmic Solution** 


### A drop that ACTS like an ointment

- GENTAMICIN SULFATE Efficacious, broad-spectrum antibiotic
- BETAMETHASONE ACETATE—Rapid anti-inflammatory corticosteroid
- DURAFILM Surfactant extends medicinal contact time to cornea and conjunctiva



### Effective management of both chronic keratoconjunctivitis sicca (KCS) and Pannus

- · Promotes conjunctival and corneal health while reducing inflammation
- Increases tear production
- Sterile formulation that reduces risk of irritation or secondary infection



Please Contact Us At:



53 Industrial Circle Lancaster, PA 17601



Phone: 1-800-233-0210 Online: www.pennvet.com